News and Announcements
Cellmid’s Clinical Study Published
- Published March 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology.
KEY TAKEAWAYS:
- The paper also describes the results of the blinded, placebo controlled clinical study of topical formulations containing the lead inhibitor in men and women. The paper can be accessed via the Journal website.
- Advangen’s technology is based around the inhibition of FGF5, an important molecule in the hair cycle that signals hair follicles to stop producing hair and rest.
- The peer-reviewed publication of these data represents an important step for the Company’s subsidiary, Advangen, and strengthens the position in the market of its products as effective hair loss treatments based on validated scientific rationale.
The lead compound identified through the screening method, named MTP3, has been shown to be almost seven times more effective in inhibiting FGF5 than previous extracts and is now included in all évolis® branded products. The data generated through the compound screening is also the subject of a patent application, currently under examination.
“The identification of single molecule inhibitors rather than whole botanical extracts represents a significant improvement in the precision of the Company’s évolis® hair loss treatments, and resulted from a substantial body of work by our dedicated Japanese research team”, said the study’s lead author Dr Dominic Burg. “The compelling clinical results highlight the utility of évolis® products against pattern hair loss in both men and women” he added.
Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
